Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylpromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.78 |
| ▸ | HTR1A | P08908 | 6/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.78 |
| ▸ | DRD3 | P35462 | 6/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.78 |
| ▸ | DRD1 | P21728 | 5/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.78 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpromazine SCHEMBL409663 | 1.00 | GFER (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL21293802 | 0.90 | GFER (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL15789014 | 0.89 | CHRM2 (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL15789013 | 0.89 | CHRM2 (0.82) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL18994 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL29354434 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL18993 | 0.88 | CHRM2 (1.00) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Cyamemazine SCHEMBL15841313 | 0.88 | GFER (0.77) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| Methylpromazine SCHEMBL2774391 | 0.87 | CHRM2 (0.97) | GFERCHRM2HTR1ACHRM1ADRA1A | |
| SCHEMBL21318406 | 0.81 | HTR1A (0.70) | GFERCHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104676-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104680-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104678-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104679-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | ANP TECHNOLOGIES, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | FULGENT GENETICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12544342-B2 | Pharmaceutical composition containing taxane nanoaggregates and use thereof | FULGENT GENETICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH INC (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2006113914-A2 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382312-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | HRH1 1205/4885GFER 3672/4885CHRM2 4632/4885 |
| US-20260078219-A1 | Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof | HAO2, HRH1, PHB1 | HRH1 2/4885GFER 3312/4885CHRM2 224/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | HRH1 2287/4885GFER 210/4885CHRM2 3064/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | HRH1 1709/4885GFER 915/4885CHRM2 3821/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | HRH1 3316/4885GFER 530/4885CHRM2 3976/4885 |
| US-12544342-B2 | Pharmaceutical composition containing taxane nanoaggregates and use thereof | VHL, LPXN, PLEC | HRH1 4249/4885GFER 4867/4885CHRM2 3611/4885 |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CD47, PBK, CD4 | HRH1 3078/4885GFER 4444/4885CHRM2 3332/4885 |
| US-12559503-B2 | Anthelmintic aza-benzothiophene and aza-benzofuran compounds | HDAC5, NR5A2, HRH4 | HRH1 22/4885GFER 805/4885CHRM2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.